Atossa Therapeutics Identifies New Anti-Cancer Compounds for ER-Positive Breast Cancer
Event summary
- Atossa Therapeutics published a peer-reviewed preclinical study in npj Breast Cancer on July 20, 2026.
- Five novel (Z)-endoxifen-related compounds demonstrated potent anti-cancer activity in ER-positive breast cancer models.
- Compounds showed activity in ESR1-mutant models and synergistic effects when combined with abemaciclib.
- The study was conducted in collaboration with Mayo Clinic.
The big picture
Atossa Therapeutics' discovery of novel (Z)-endoxifen-related compounds addresses a critical unmet need in treating endocrine-resistant ER-positive breast cancer. The findings could expand the company's endoxifen platform, particularly for patients with ESR1 mutations who have limited treatment options. This strategic move aligns with broader industry efforts to develop targeted therapies for resistant cancer subtypes.
What we're watching
- Clinical Translation
- Whether the preclinical findings will translate into clinical efficacy and safety in human trials.
- Combination Therapy
- The potential for these compounds to be developed as combination therapies with CDK4/6 inhibitors like abemaciclib.
- Regulatory Pathway
- The pace at which Atossa Therapeutics can advance selected candidates through in vivo safety and efficacy studies.